F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Patent
Method of genotyping and phenotyping hepatitis b viruses resistant to antiviral molecules
TL;DR: In this paper, a method of preparation of HBV genomic amplicons is presented, which makes it possible, using the same amplicon obtained from a patient, to evaluate HBV strains resistant to antiviral agents by analyzing, their genotype, phenotype and their replicative capacity.
Comparison of the antiviral activity of Adefovir (ADV) and Teno- fovir (TDF) on hepatitis B virus (HBV) in HIV-HBV co-infected pa- tients.
Karine Lacombe,Joël Gozlan,Anders Boyd,Pierre-Yves Boëlle,Jean-Michel Molina,Patrick Miailhes,Caroline Lascoux-Combe,Lawrence Serfaty,Fabien Zoulim,Pierre-Marie Girard,Hôtel Dieu +10 more
TL;DR: In this article, the authors present a set of rules for different types of re-evaluation problems in the context of a re-invariant re-construction problem.
Journal ArticleDOI
Sofosbuvir plus ribavirin and sofosbuvir plus daclatasvir-based regimens are suboptimal in genotype 2 patients: real-life experience
Christophe Hézode,V. de Ledinghen,Georges Haour,Jean-Pierre Bronowicki,Fabien Zoulim,Dominique Larrey,Metivier Sophie,Tran Albert,M. Patrick,Didier Samuel,Olivier Chazouillères,C. Stephane,D. Celine,F. Helene,J.-M. Pawlotsky,C. Fabrice,Pol Stanislas +16 more
Journal ArticleDOI
Bithérapie par analogues dans le traitement de l’hépatite chronique B : de novo ou en cas d’échec
TL;DR: Les combinaisons therapeutiques d’emblee previennent l’apparition de resistance a court terme pour les molecules ayant une faible barriere genetique and ameliore le controle de l”infection.
Journal ArticleDOI
Treatment of human immunodeficiency virus and hepatitis B virus infections
TL;DR: Although virally attenuated clotting factor concentrates are now safe with respect to transmission of HBV and HIV, consideration needs to be given as to the possible benefits of including those with haemophilia in the clinical assessment.